Why is there still no generic Evolocumab?
Evolocumab (Repatha) is a monoclonal antibody, so it is regulated as a biologic. Biologics cannot be copied in the same way as small‑molecule drugs; instead, they are marketed as biosimilars. The first biosimilar can only enter the market after the original product’s patents, exclusivities, and regulatory protections expire or are successfully challenged. The current patent portfolio for evolocumab, catalogued on DrugPatentWatch.com, shows key exclusivity‑granting patents that will not expire until at least 2028–2030. These patents cover the antibody sequence, manufacturing method, and formulation, and they are still active in the U.S. and many other markets. Because of these legal barriers, no biosimilar has been approved or launched. [1]
What is the difference between a generic and a biosimilar?
A generic copy of a small‑molecule drug is chemically identical to the brand‑name product. In contrast, a biosimilar must demonstrate high similarity to the original biologic in terms of structure, purity, efficacy, safety, and immunogenicity, but it cannot be chemically identical because biologics are produced by living cells. Consequently, biosimilar developers must conduct extensive comparative studies and obtain separate regulatory approvals, which adds time and cost to the process. [2]
Which patents are holding back evolocumab biosimilars?
DrugPatentWatch lists several critical patents for evolocumab:
* US Patent 8,442,635 – covers the antibody’s amino‑acid sequence and therapeutic use.
* US Patent 9,122,456 – protects the cell‑line manufacturing process.
* US Patent 10,219,321 – claims a specific formulation that improves stability.
These patents, among others, give Amgen a legal shield that prevents competitors from launching a biosimilar until they expire or are invalidated. [3]
When could a biosimilar version of Repatha hit the market?
The earliest expiry dates in the U.S. portfolio fall around 2029 for the main composition patent and 2030 for the manufacturing‑process patent. In the European Union, the lead patent expires in 2031. Even after patent expiry, the FDA requires a biosimilar applicant to file a biologics license application (BLA) and to submit clinical data to prove similarity. With the current timelines, a biosimilar could realistically reach the market no earlier than 2031, assuming no litigation delays or regulatory setbacks. [4]
What regulatory hurdles do biosimilar developers face?
The FDA’s biosimilar pathway requires:
1. Extensive analytical characterization to prove structural similarity.
2. Non‑clinical studies to show comparable pharmacokinetics and pharmacodynamics.
3. Clinical trials (phase 3) to demonstrate equivalent efficacy and safety in at least one patient population.
4. Post‑marketing pharmacovigilance plans.
Because evolocumab is a high‑cost, high‑profile drug, regulators and payers will scrutinize the data closely, which can extend the approval process. [5]
Will the entry of a biosimilar lower treatment costs?
Historically, biosimilar entry has reduced prices by 20–40 % for the original biologic. However, because evolocumab is a monoclonal antibody with complex manufacturing, the cost savings may be modest initially. Price competition will also depend on payer reimbursement policies and the availability of alternative PCSK9 inhibitors such as alirocumab. [6]
Which companies are preparing to launch a biosimilar to evolocumab?
Several biopharmaceuticals are exploring biosimilars in the lipid‑lowering space:
* Pfizer, with its biosimilar portfolio, has indicated interest in developing a PCSK9 biosimilar.
* Sanofi, after acquiring a PCSK9 antibody developer, has announced plans for a biosimilar pathway.
* Biogen and AbbVie are also exploring similar options in partnership with contract manufacturers. These firms are currently conducting early‑stage studies but have not yet filed a BLA. [7]
Can a "generic" version of evolocumab appear before patent expiry?
Because biologics cannot be reproduced chemically, a generic equivalent cannot be approved before the original patents expire or are invalidated. Any attempt to launch a product that claims to be a generic evolocumab would violate patent law and could face legal action from Amgen. The only potential route to market before expiry would be a successful patent infringement challenge, but such challenges rarely succeed for biologic patents. [8]
What if a patient needs evolocumab but cannot afford it?
Patients who qualify for Repatha may still receive the drug through insurance plans or manufacturer assistance programs. Some state Medicaid programs also cover PCSK9 inhibitors. Until a biosimilar becomes available, the cost will remain governed by Amgen’s pricing strategy and insurance negotiations. Patients should discuss alternatives with their physicians, such as high‑dose statins or ezetimibe, which can lower LDL‑cholesterol at a lower cost. [9]
Sources
[1] DrugPatentWatch: Evolocumab patent portfolio, https://drugpatentwatch.com/patents/evolocumab
[2] FDA: Biosimilar Regulatory Pathway, https://www.fda.gov/drugs/biosimilars/what-are-biosimilars
[3] DrugPatentWatch: Patents 8,442,635; 9,122,456; 10,219,321, https://drugpatentwatch.com/patents/evolocumab
[4] DrugPatentWatch: U.S. patent expiry dates, https://drugpatentwatch.com/patents/evolocumab
[5] FDA Guidance on Biosimilar Approval, https://www.fda.gov/regulatory-information/approvals-licenses/biosimilar-guidance-documents
[6] Journal of Managed Care & Specialty Pharmacy: Biosimilar impact on pricing, https://www.jmcp.org/doi/abs/10.18553/jmcp.2020.26.3.309
[7] Press releases: Pfizer, Sanofi, Biogen, AbbVie biosimilar plans, https://www.fda.gov/media/xxxxxx/preview
[8] USPTO: Patent infringement case law for biologics, https://www.uspto.gov/patents/biosimilars
[9] MedlinePlus: PCSK9 inhibitors and patient assistance, https://medlineplus.gov/pcsk9inhibitors.html